Advanced Analytics Drive Biologics Characterization
Research facilities are integrating advanced size exclusion chromatography (SEC) with multi-modal detectors to enable more comprehensive analytics for biologics. The Molecular Biophysics lab in Brno, for example, is coupling systems with multi-wavelength detectors for light scattering and differential refractive index to accelerate both R&D and GMP analytics. This trend toward high-content data capture requires robust integration with LIMS and ELN systems.
- In gene therapy applications, SEC-MALS is proving crucial for quantifying critical quality attributes (CQAs) of adeno-associated virus (AAV) vectors, such as accurately measuring the ratio of empty to full capsids, which is a key impurity that can impact product safety and efficacy. This technique has demonstrated strong correlation with traditional methods like analytical ultracentrifugation (SV-AUC) for this purpose. - The lack of standardized data management tools and assays in the cell and gene therapy sector creates significant inefficiencies, especially as production volumes increase. This challenge is amplified in autologous therapies, where each batch is unique to a patient, leading to a direct increase in data collection for batch records, supply chain tracking, and quality control. - Integrating ELN and LIMS systems is a strategic necessity to overcome data silos that hinder operational efficiency in biopharma, with some reports indicating that 53% of large pharmaceutical organizations are impacted by this issue. A unified digital ecosystem is foundational for enabling AI and machine learning applications in drug discovery and manufacturing, which have shown the potential to significantly increase the success rates of drugs in Phase 1 trials. - Artificial intelligence and machine learning are being increasingly applied to optimize viral vector manufacturing by improving the coding sequences of vector components for greater stability and efficacy. AI can also predict the genotoxicity of viral vectors and help analyze empty-to-full capsid ratios during production. - The biotech funding climate has shifted towards larger, but fewer, investment rounds, with a focus on companies with strong science and experienced leadership. Venture capital funding in 2024 surpassed pre-pandemic levels, but investors are showing a preference for de-risked, late-stage assets in Phase 2 and beyond. - For CDMOs, the current biotech capital pullback has led to program delays and fewer orders, causing some to reduce specialized cell and gene therapy services. This environment is expected to drive industry consolidation and retooling of therapeutic pipelines through late 2025 and early 2027. - A significant challenge in cell and gene therapy manufacturing is the high cost associated with legacy processes that are complex and difficult to scale, particularly for autologous CAR-T therapies. The lack of standardization across the industry, with at least 10 different AAV serotypes in use, complicates the development of platform manufacturing and analytical approaches. - Advanced analytical techniques like Cation Exchange Chromatography (CEX) are being coupled with MALS to analyze charge variants of biologics. This provides deeper insights into degradation pathways and ensures that process changes, such as switching to a higher-yielding cell line, do not significantly alter the molecular properties of the biosimilar product.
